Evinature

Company Overview

Snapshot

Founded in April 2021 by Apan Amos Damri, Dr. Prof. Shomron Ben-Horin M.D., and Nir Salomon ChB, Evinature operates with 11–50 employees. The company has raised $6.5M across three funding rounds from one investor. In February 2024, Evinature secured a seed funding round.

Business overview

Evinature develops natural, evidence-based nutraceuticals for gut health, combining modern science with traditional botanical knowledge. The company offers well-researched solutions and personalized guidance based on individual wellness goals, supported by ongoing digital check-ins and optional clinic-based care. Evinature serves health-minded communities globally, focusing on the Health Tech & Life Sciences sector with products like CurQD® and DivertX, and operates across B2B, B2B2C, and B2C business models.

Strategic signal

In May 2024, Evinature's CurQD® trial was spotlighted at the CCF’s IBD Innovate Conference, highlighting the company's commitment to advancing research in inflammatory bowel disease (IBD). This signals strong scientific validation and growing recognition within the medical community for Evinature's innovative approach to IBD patient care.

Company Intelligence Q&A

What is Evinature's core focus?

Evinature focuses on developing clinically proven, evidence-based nutraceuticals for gut health, combining modern science with traditional botanical knowledge to offer natural solutions.

When was Evinature founded and by whom?

Evinature was founded in April 2021 by Apan Amos Damri, Dr. Prof. Shomron Ben-Horin M.D., and Nir Salomon ChB.

What was a significant recent development for Evinature's CurQD® product?

In May 2024, Evinature's CurQD® trial was spotlighted at the CCF’s IBD Innovate Conference, showcasing its advancements in IBD treatment.

How is Evinature expanding accessibility to its IBD treatments?

In April 2024, Evinature integrated its healthcare startup across 35 US medical centers to streamline IBD treatment accessibility.